Identifying and Overcoming Challenges in Developing Effective Treatments for Usher 1B: A Workshop Report

Overview

Journal Transl Vis Sci Technol

Specialties Biomedical Engineering
Ophthalmology

Date 2023 Feb 1

PMID 36723965

Authors

Shannon E Boye

Todd Durham

Amy Laster

Claire M Gelfman

Jose-Alain Sahel

Affiliations

Soon will be listed here.

Abstract

Purpose: To identify challenges and opportunities for the development of treatments for Usher syndrome (USH) type 1B.

Methods: In September 2021, the Foundation Fighting Blindness hosted a virtual workshop of clinicians, academic and industry researchers, advocates, and affected individuals and their families to discuss the challenges and opportunities for USH1B treatment development.

Results: The workshop began with insights from individuals affected by USH1B. Presentation topics included myosin VIIA protein function in the ear and eye and its role in disease pathology; challenges with the USH1B mouse model most used in disease research to date; new investigations into alternative disease models that may provide closer analogues to USH1B in the human retina, including retinal organoids and large animal models; and learnings from and limitations of available disease natural history data. Participants discussed the need for an open dialogue between researchers and regulators to design USH1B clinical trials with appropriate outcome measures of vision improvement, along with multimodal imaging of the retina and other testing approaches that can help inform trial designs. The workshop concluded with presentations and a roundtable reviewing emerging treatments, including USH1B-targeted genetic augmentation therapy and gene-agnostic approaches.

Conclusions: Initiatives like this workshop are important to foster all stakeholders in support of achieving the shared goal of treating and curing USH1B.

Translational Relevance: Presentations and discussions focused on overcoming disease modeling and clinical trial design challenges to facilitate development, testing, and implementation of effective USH1B treatments.

Citing Articles

Key challenges in developing a gene therapy for Usher syndrome: machine-assisted scoping review.

Bhat R, Nallamothu B, Shethia F, Chhaya V, Khambholja K J Community Genet. 2024; 15(6):735-747.

PMID: 39549230 PMC: 11645336. DOI: 10.1007/s12687-024-00749-0.

Multicentric Longitudinal Prospective Study in a European Cohort of MYO7A Patients: Disease Course and Implications for Gene Therapy.

Testa F, Carreno E, van den Born L, Melillo P, Perea-Romero I, Di Iorio V Invest Ophthalmol Vis Sci. 2024; 65(6):25.

PMID: 38884554 PMC: 11185270. DOI: 10.1167/iovs.65.6.25.

References

Bahloul A, Michel V, Hardelin J, Nouaille S, Hoos S, Houdusse A . Cadherin-23, myosin VIIa and harmonin, encoded by Usher syndrome type I genes, form a ternary complex and interact with membrane phospholipids. Hum Mol Genet. 2010; 19(18):3557-65. PMC: 2928128. DOI: 10.1093/hmg/ddq271. View

Boughman J, Vernon M, Shaver K . Usher syndrome: definition and estimate of prevalence from two high-risk populations. J Chronic Dis. 1983; 36(8):595-603. DOI: 10.1016/0021-9681(83)90147-9. View

Lopes V, Williams D . Gene Therapy for the Retinal Degeneration of Usher Syndrome Caused by Mutations in MYO7A. Cold Spring Harb Perspect Med. 2015; 5(6). PMC: 4448706. DOI: 10.1101/cshperspect.a017319. View

Wolfrum U, Schmitt A . Rhodopsin transport in the membrane of the connecting cilium of mammalian photoreceptor cells. Cell Motil Cytoskeleton. 2000; 46(2):95-107. DOI: 10.1002/1097-0169(200006)46:2<95::AID-CM2>3.0.CO;2-Q. View

Liu X, Vansant G, Udovichenko I, Wolfrum U, Williams D . Myosin VIIa, the product of the Usher 1B syndrome gene, is concentrated in the connecting cilia of photoreceptor cells. Cell Motil Cytoskeleton. 1997; 37(3):240-52. DOI: 10.1002/(SICI)1097-0169(1997)37:3<240::AID-CM6>3.0.CO;2-A. View

Volland S, Hughes L, Kong C, Burgess B, Linberg K, Luna G . Three-dimensional organization of nascent rod outer segment disk membranes. Proc Natl Acad Sci U S A. 2015; 112(48):14870-5. PMC: 4672767. DOI: 10.1073/pnas.1516309112. View

Weil D, Levy G, Sahly I, Levi-Acobas F, Blanchard S, El-Amraoui A . Human myosin VIIA responsible for the Usher 1B syndrome: a predicted membrane-associated motor protein expressed in developing sensory epithelia. Proc Natl Acad Sci U S A. 1996; 93(8):3232-7. PMC: 39588. DOI: 10.1073/pnas.93.8.3232. View

Adato A, Michel V, Kikkawa Y, Reiners J, Alagramam K, Weil D . Interactions in the network of Usher syndrome type 1 proteins. Hum Mol Genet. 2004; 14(3):347-56. DOI: 10.1093/hmg/ddi031. View

Millan J, Aller E, Jaijo T, Blanco-Kelly F, Gimenez-Pardo A, Ayuso C . An update on the genetics of usher syndrome. J Ophthalmol. 2011; 2011:417217. PMC: 3017948. DOI: 10.1155/2011/417217. View

10.

Lefevre G, Michel V, Weil D, Lepelletier L, Bizard E, Wolfrum U . A core cochlear phenotype in USH1 mouse mutants implicates fibrous links of the hair bundle in its cohesion, orientation and differential growth. Development. 2008; 135(8):1427-37. DOI: 10.1242/dev.012922. View

11.

Li S, Mecca A, Kim J, Caprara G, Wagner E, Du T . Myosin-VIIa is expressed in multiple isoforms and essential for tensioning the hair cell mechanotransduction complex. Nat Commun. 2020; 11(1):2066. PMC: 7190839. DOI: 10.1038/s41467-020-15936-z. View

12.

Boeda B, El-Amraoui A, Bahloul A, Goodyear R, Daviet L, Blanchard S . Myosin VIIa, harmonin and cadherin 23, three Usher I gene products that cooperate to shape the sensory hair cell bundle. EMBO J. 2002; 21(24):6689-99. PMC: 139109. DOI: 10.1093/emboj/cdf689. View

13.

Jacobson S, Cideciyan A, Gibbs D, Sumaroka A, Roman A, Aleman T . Retinal disease course in Usher syndrome 1B due to MYO7A mutations. Invest Ophthalmol Vis Sci. 2011; 52(11):7924-36. PMC: 3263772. DOI: 10.1167/iovs.11-8313. View

14.

Fu X, Huu V, Duan Y, Kermany D, Valentim C, Zhang R . Clinical applications of retinal gene therapies. Precis Clin Med. 2022; 1(1):5-20. PMC: 8982485. DOI: 10.1093/pcmedi/pby004. View

15.

Adato A, Weil D, Kalinski H, Pel-Or Y, Ayadi H, Petit C . Mutation profile of all 49 exons of the human myosin VIIA gene, and haplotype analysis, in Usher 1B families from diverse origins. Am J Hum Genet. 1997; 61(4):813-21. PMC: 1716000. DOI: 10.1086/514899. View

16.

Schietroma C, Parain K, Estivalet A, Aghaie A, de Monvel J, Picaud S . Usher syndrome type 1-associated cadherins shape the photoreceptor outer segment. J Cell Biol. 2017; 216(6):1849-1864. PMC: 5461027. DOI: 10.1083/jcb.201612030. View

17.

El-Amraoui A, Safieddine S, Nouaille S, Perfettini I, Lecuit M, Cossart P . Vezatin, a novel transmembrane protein, bridges myosin VIIA to the cadherin-catenins complex. EMBO J. 2000; 19(22):6020-9. PMC: 305826. DOI: 10.1093/emboj/19.22.6020. View

18.

Ferrari S, Di Iorio E, Barbaro V, Ponzin D, Sorrentino F, Parmeggiani F . Retinitis pigmentosa: genes and disease mechanisms. Curr Genomics. 2011; 12(4):238-49. PMC: 3131731. DOI: 10.2174/138920211795860107. View

19.

Marazita M, Ploughman L, Rawlings B, Remington E, Arnos K, Nance W . Genetic epidemiological studies of early-onset deafness in the U.S. school-age population. Am J Med Genet. 1993; 46(5):486-91. DOI: 10.1002/ajmg.1320460504. View

20.

Weil D, Blanchard S, Kaplan J, Guilford P, Gibson F, Walsh J . Defective myosin VIIA gene responsible for Usher syndrome type 1B. Nature. 1995; 374(6517):60-1. DOI: 10.1038/374060a0. View